The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer

References

• American Cancer Society. Facts and Figures, 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
   Google Scholar
• Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012 Oct;21(10):1031–1037.
   PubMed Web of Science ®Google Scholar
• Tewari KS. Clinical implications for cediranib in advanced cervical cancer. Lancet Oncol. 2015 Nov;16(15):1447–1448.
   PubMed Web of Science ®Google Scholar
• Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999 Jan;288(1):371–378.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008 Oct;62(5):779–786.
   PubMed Web of Science ®Google Scholar
• Xu L, Zuch CL, Lin YS, et al. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. Cancer Chemother Pharmacol. 2008 Apr;61(4):607–614.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Thomsen K, Licko V, et al. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol. 1999 Jan-Feb;27(1):14–21.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin M, Talpaz G, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001 Feb 1;19(3):843–850.
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren J, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001 Feb 1;19(3):851–856.
   PubMed Web of Science ®Google Scholar
• Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006 Nov;103(2):489–493.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009 Mar 1;27(7):1069–1074.
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Feng Gaoc F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013 Jul;130(1):64–68.
   PubMed Web of Science ®Google Scholar
• Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1179–1184.
   PubMed Web of Science ®Google Scholar
• Schefter T, Winter K, Kwon JS, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):101–105.
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014 Feb 20;370(8):734–743.
   PubMed Web of Science ®Google Scholar
• Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomized, phase 3 trial (NRG oncology-gynecologic oncology group protocol 240). Lancet Oncol. 2015. Mar;16(3):301–311.
   PubMed Web of Science ®Google Scholar
• Morris M, Eifel PR, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999. Apr 15;340(15):1137–1143.
   PubMed Web of Science ®Google Scholar
• Bevacizumab [package insert]. San Francisco, CA: Genetech, Inc. Available from: https://www.gene.com/download/pdf/avastin_prescribing.pdf
   Google Scholar
• Mourad JJ, Des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008 May;19(5):927–934.
   PubMed Web of Science ®Google Scholar
• Kerbel SK, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004 Jun;4(6):423–436.
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Martin-Manso G, Maxhimer JB, et al. Regulation of nitric oxide signaling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer. 2009;9(3):182–194.
   PubMed Web of Science ®Google Scholar
• Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010 May;11(5):465–475.
   PubMed Web of Science ®Google Scholar
• Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011 Dec;6(4):253–258.
   PubMed Web of Science ®Google Scholar
• Seet RCS, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. Qjm. 2012 Jan;105(1):69–75.
   PubMed Web of Science ®Google Scholar
• Singer S, Grommes C, Reiner AS. Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015 Jul;20(7):806–811.
   PubMed Web of Science ®Google Scholar
• Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J. 2008 Oct;29(19):2325–2326.
   PubMed Web of Science ®Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009 Jun;10(6):559–568.
   PubMed Web of Science ®Google Scholar
• Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009 Jun;62(6):707–709.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbach L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005 Sep 1;91(3):173–180.
   PubMed Web of Science ®Google Scholar
• Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011 Jun;114(6):1609–1616.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015 Nov;16(15):1515–1524.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010 Aug 1;28(22):3562–3569.
   PubMed Web of Science ®Google Scholar
• Cetina L, Crombet T, Jiménez-Lima R, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biol Ther. 2015;16(5):684–689.
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008 Jul 1;14(13):4200–4205.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentration and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006 Feb 15;12(4):1317–1324.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec;127(3):451–455.
   PubMed Web of Science ®Google Scholar
• Pasquier E, Honoré S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat. 2006 Feb-Apr;9(1–2):74–86.
   PubMed Web of Science ®Google Scholar
• Minion LE, Chase DM, Farley JH, et al. Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a fesiblity study. Gynecol Oncol Res Pract. 2016 Apr 14;3:4.
   Google Scholar
• Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004 Feb 1;64(3):821–824.
   PubMed Web of Science ®Google Scholar
• Gerald D, Chintharlapalli S, Augustin HG, et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013 Mar 15;73(6):1649–1657.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799–808.
   PubMed Web of Science ®Google Scholar
• Minion LE, Bai J, Monk BJ, et al. A markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015 Jun;137(3):490–496.
   PubMed Web of Science ®Google Scholar
• Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent/refractory cervical cancer. J Iimmunother Cancer.2013;1(1):231. 2014;32(15_suppl (May 20 Supplement)):5610.
   Google Scholar
• Heeren AM, Punt S, Bleeker MCG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016 Jul;29(7):753–763.
   PubMed Web of Science ®Google Scholar
• Frenel JS, Le Tourneau C, O’Neil BH, et al. Pembrolizumab in patients with advanced cervical squamous cell cancer: preliminary results from the phase Ib KEYNOTE-028 study. Abstract 2016 ASCO.
   Google Scholar